EAM
AMRI

EverPoint Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

EverPoint Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-800,000
Closed -$16.2M – 588
2015
Q2 		$16.2M Sell
800,000
-100,000
-11% -$1.93M 0.3% 99
2015
Q1 		$15.8M Buy
+900,000
New +$15.3M 0.3% 101

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EverPoint Asset Management's AMRI Position: Q3 2015 in Review

EverPoint Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q3 2015, closing a stake of 800,000 shares — an estimated $16.2M sold.

EverPoint Asset Management first reported a position in AMRI in Q1 2015 and held it in 2 quarters. The position peaked at $16.2M in Q2 2015. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2015.

  • EverPoint Asset Management reported no remaining Albany Molecular Research Inc position as of Q3 2015 after selling out during the quarter.
  • EverPoint Asset Management sold 800,000 Albany Molecular Research Inc shares in Q3 2015, an estimated $16.2M.
  • EverPoint Asset Management first reported a position in Albany Molecular Research Inc in Q1 2015 and held it in 2 quarters.
  • EverPoint Asset Management's Albany Molecular Research Inc position peaked at $16.2M in Q2 2015.
  • 143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2015.

Based on EverPoint Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.